Compare BridgeBio Pharma Inc (BBIO) vs Citigroup Inc. (C) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Citigroup Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Citigroup Inc. trades at $135.95 (market cap $227.75B). The key difference: Citigroup Inc. is far larger — about 13.9× BridgeBio Pharma Inc's market cap, and Citigroup Inc. pays a 1.97% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | C | |
|---|---|---|
Market Cap | $16.36B | $227.75B |
Sector | Health | Financials |
52-Week High | $90.17 | $145.67 |
52-Week Low | $47.29 | $92.59 |
Enterprise Value | $18.14B | — |
Dividend Yield | — | 1.97% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Citigroup Inc.
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →
